New etravirine analogues as potential inhibitors of HIV-1 reverse transcriptase and Mycobacterium tuberculosis

Vol. 1, 2019 - 108990
Poster only
Favorite this paper
How to cite this paper?
Abstract

For the treatment of HIV-TB co-infection, many drugs are used concomitantly for a long time, which decrease patient compliance. Therefore, it is necessary to develop new compounds with multi-target characteristics, which can treat HIV-TB with greater effectiveness and less toxicity. Therefore, the objective of this work was the synthesis of new analogues of etravirine, used in anti-HIV therapy, containing in their structure isoniazid and pyrazinamide, applied in TB treatment. These molecules were designed via molecular hybridization tool between the DAPY skeleton, the main pharmacophoric fragment of etravirine, the 1,2,3-triazole ring and isatin nucleus. Until now, ten products were synthesized, four intermediates and six new final products, with a high degree of purity and in moderate yields. The final compounds are being evaluated as to the inhibitory activity on a TRHXB2 RNA-dependent DNA polymerase (RDDP), using recombinant purified HIV-1 enzyme, and antimycobacterial activity in drugs susceptible and resistant M. tuberculosis.

Track
  • 2. Medicinal Chemistry of Synthetic Compounds
Keywords
reverse transcriptase
HIV-1
TB
DAPY